12.29.20

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi

Source: Eyenovia

12.16.20

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia

Source: Eyenovia

12.03.20

FDA Approves Eyenovia’s IND Application for MicroLine for Presbyopia, Allowing for Phase 3 Trials

Source: Eyenovia

10.12.20

Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

Source: Bausch Health

10.08.20

Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting

Source: Eyenovia

08.11.20

Eyenovia and Arctic Vision Announce License Agreement to Develop and Commercialize Products in Greater China and South Korea

Source: Eyenovia

10.29.19

Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipeline

Source: Eyenovia

06.05.19

Eyenovia Enrolls First Patient in Phase 3 CHAPERONE Study for Progressive Myopia

Source: Eyenovia

05.06.19

Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS

Source: Eyenovia

02.25.19

Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasis

Source: Eyenovia

View more stories